Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 1, 2024
Language: Английский
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: Oct. 9, 2023
Head and neck squamous cell carcinoma (HNSCC), as a complex variable malignancy, poses significant threat to human health. Since the intricate association between HPV HNSCC emerged, its role within TME has garnered extensive attention. HPV+HNSCC exhibits distinct immunological characteristics TME, intricately intertwined with mechanisms of immune evasion. employs multifaceted pathways intervene in metabolic regulation exerting influence over functionality neoplastic genesis. Furthermore, heightened reactivity exhibited by augments responses interventions such checkpoint inhibitors. Therefore, amidst current limitations therapeutic approaches, immunotherapy stands promising strategy overcome conventional confines treating HNSCC. This article comprehensively outlines impact on inception progression while discussing amalgamation immunotherapeutic strategies. By intervening reciprocal interactions potential modulate efficacy immune-based treatments becomes evident. Concurrently, synthesis pertinent biomarker development is summarized. Such endeavors hold paramount significance for personalized approaches more effective management patients.
Language: Английский
Citations
7
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: June 29, 2023
Head and neck cancer (HNC) ranks as the sixth most prevalent type of globally accounts for about 4% all types cancer. Among HNC, are head squamous cell carcinoma (HNSCC) with clinical therapies that include surgery, radiation therapy, chemotherapy, immunotherapy, targeted multimodal treatments. In recent years, chimeric antigen receptor (CAR)-T immunotherapy has significantly transformed therapeutic approaches leukemia lymphoma garnered increased attention a potential treatment wide range cancers. However, CAR-T in solid tumors, especially HNSCCs, lags behind due to paucity tumor-specific antigens, high levels tumor heterogeneity, immunosuppressive microenvironment, risk treatment-related toxicities off-target adverse events HNSCCs. The objective this review is explore advancement therapy We aim outline antigens highlight challenges solutions, discuss relevant combination therapies. Our presents comprehensive overview developments provides valuable insights into future research avenues.
Language: Английский
Citations
6
Diagnostics, Journal Year: 2023, Volume and Issue: 13(22), P. 3396 - 3396
Published: Nov. 7, 2023
Introduction: Neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte (LMR), and pallets-to-lymphocyte (PLR) are currently validated as cheap accessible biomarkers in different types of solid tumors, including head neck cancers (HNC). The purpose the study: To evaluate possible purposes biomarker value NLR, PLR, MLR recorded pre-treatment (radiotherapy/chemotherapy) HNC. Materials methods: From 190 patients with HNC included oncology records outpatient clinic Craiova County Emergency Hospital (from January 2002 to December 2022), 39 cases met inclusion criteria (squamous cell carcinoma possibility calculate (chemotherapy/radiotherapy) MLR. Overall survival (OS) values were correlated Results: median for 6.15 (1.24–69), 200.79 (61.3–1775.0), 0.53 (0.12–5.5), respectively. In study, mean 2.88, 142.97, 0.36, respectively, obtained. OS study group was 11 months (1–120). Although a negative Pearson’s correlation present, relationship between variables only weak, R = 0.07, p 0.67, 0.02, 0.31, 0.62 being related MLR, OS. calculated (1.53, 90.32, 0.18, respectively) NLR < 2 ≥ 6 (23.5, 232.78, 0.79, respectively). 17.4 13 months, Conclusions: comparative analysis data highlights benefit low NLR. role not borderline (between 6) prognostic marker HNSCC but also PLR score must be defined future. Prospective studies more uniformly selected could demonstrate treatment stratification through intensification or de-escalation non-surgical curative HNSCC.
Language: Английский
Citations
6
Oral Oncology Reports, Journal Year: 2024, Volume and Issue: 9, P. 100188 - 100188
Published: Jan. 29, 2024
At present, PD-L1 scoring is the gold standard in evaluating a cancer patient's suitability for receiving PD-1/PD-L1 checkpoint inhibitor immunotherapy (CIT). Either tumor proportion score (TPS) or combined positive (CPS) can be used to select head and neck squamous cell carcinoma (HNSCC) patients immunotherapy. However, current clinical workflow only uses one histological section scoring. The considerable under-sampling of tissue may lead an inaccurate score, potentially affecting treatment outcomes. In this study, we selected formalin-fixed, paraffin-embedded (FEPE) blocks from five HNSCC patients. thickness each these allowed us determine at depths with adjacent layers separated by 500 μm. We found that although there are variations scores among different sections, generally consistent across block patient. also compared TPS CPS values sampling frequencies single sections 1000, 1500, 2000 all cases, fall within deviation average depths. Considering threshold decisions, our results suggest cases where patients' close values, two μm should considered.
Language: Английский
Citations
1
Cureus, Journal Year: 2024, Volume and Issue: unknown
Published: Feb. 1, 2024
Metaplastic breast cancer (MpBC) is a rare form of known for suboptimal response to chemotherapy, high recurrence rate, poor prognosis, and limited treatment options. Recent studies have reported that MpBC has expression programmed death ligand 1 tumor-infiltrating lymphocytes, indicating the potential effectiveness immunotherapy (IO) in MpBC. In addition, several reports demonstrated activity IO this case report, we present recurrent achieved durable, rapid, complete remission with atezolizumab (anti-PD-L1) nab-paclitaxel continued even after discontinued therapy.
Language: Английский
Citations
1
Journal of Oral Pathology and Medicine, Journal Year: 2024, Volume and Issue: 53(4), P. 238 - 245
Published: April 1, 2024
Abstract Background The differences between existing preclinical models and the tumor microenvironment in vivo are one of significant challenges hindering cancer therapy development. Patient‐derived organoids (PDTO) can highly retain heterogeneity. Thus, it provides a more reliable platform for research biology, new drug screening, precision medicine. Methods We conducted systematic review to summarise characteristics models, advantages patient‐derived reconstructing microenvironment, latest progress. Moreover, this study deciphers organoid culture technology clinical treatment head neck achieve better transformation. Studies were identified through comprehensive search Ovid MEDLINE (Wolters Kluwer), PubMed (National Library Medicine), web Science (Thomson Reuters) and, Scopus (Elsevier) databases, without publication date or language restrictions. Results In development, interaction cellular non‐cellular components (TME) has crucial role. Co‐culture, Air‐liquid interface culture, microfluidics, decellularized matrix have depicted great potential simulating genesis, metastasis. Conclusion An accurate determination stromal cells, immune extracellular be achieved by using PDTO model. cells also play an essential role implementing individualized cancer.
Language: Английский
Citations
1
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2024, Volume and Issue: 1879(5), P. 189138 - 189138
Published: June 16, 2024
Head and neck cancer (HNSCC) is the 8th most common in UK, with incidence increasing due to lifestyle factors such as tobacco alcohol abuse. HNSCC an immune-suppressive disease characterised by impaired cytokine secretion dysregulation of immune infiltrate. As such, immunotherapy a potential treatment option, therapeutic vaccination demonstrating greatest potential. The success dependent on informed antigen selection: ideal must be either tumour-specific or tumour-associated, well highly immunogenic. Stratification patient population for expression validated biomarkers are also vital. This review focuses latest developments immunotherapy, specifically development vaccines, highlights successes, drawbacks areas future development. Immunotherapy approaches considered include monoclonal antibodies (mAb), Oncolytic viral (OV) therapies, Immune Checkpoint Inhibitors (ICIs) vaccines.
Language: Английский
Citations
1
Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14
Published: Oct. 8, 2024
Recent strides in understanding the molecular underpinnings of head and neck cancers have sparked considerable interest identifying precise biomarkers that can enhance prognostication enable personalized treatment strategies. Immunotherapy has particularly revolutionized therapeutic landscape for squamous cell carcinoma, offering new avenues treatment. This review comprehensively examines application limitations established emerging/novel carcinoma. Established biomarkers, including well-characterized genetic mutations, protein expressions, clinical factors, been extensively studied validated practice. Novel identified through analyses, novel alterations, immune-related markers, signatures, are currently being investigated preclinical settings. Biomarkers hold potential to deepen our carcinoma biology guide The evolving paradigm predictive facilitates study individual responses specific treatments, targeted therapy immunotherapy.
Language: Английский
Citations
1
Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14
Published: Feb. 19, 2024
The KEYNOTE-048 and KEYNOTE-040 study have demonstrated the efficacy of pembrolizumab in recurrent or metastatic squamous cell carcinoma head neck (R/M HNSCC), we conducted this real-world to investigate patients with R/M HNSCC.
Language: Английский
Citations
1
Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)
Published: March 14, 2024
One of the most common oral carcinomas is squamous cell carcinoma (OSCC), bringing a heavy burden to global health. Although progresses have been made in intervention OSCC, 5 years survival patients suffering from OSCC poor like before regarding high invasiveness which causes metastasis and recurrence tumor. The relationship between pyroptosis remains be further investigated as has gained much attention. Herein, key pyroptosis-related genes were identified according Cancer Genome Atlas (TCGA) dataset. Additionally, prognostic model was constructed based upon three (CTLA4, CD5, IL12RB2) through least absolute shrinkage selection operator (LASSO) analyses, well univariate multivariate COX regression OSCC. It discovered that expression these associated with low-risk group. We also LAIR2 hub gene, whose negatively correlated risk score different immune infiltration. Finally, we proved independent factors linked overall (OS), reliable consequences could predicted by this model. Our study revealed providing insights into new treatment targets for preventing treating
Language: Английский
Citations
1